PMID- 27431004
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20170206
IS  - 1881-7823 (Electronic)
IS  - 1881-7815 (Linking)
VI  - 10
IP  - 4
DP  - 2016 Sep 5
TI  - Serum levels of RIPK3 and troponin I as potential biomarkers for predicting 
      impaired left ventricular function in patients with myocardial infarction with ST 
      segment elevation and normal troponin I levels prior percutaneous coronary 
      intervention.
PG  - 294-9
LID - 10.5582/bst.2016.01077 [doi]
AB  - The current study examined the serum levels of receptor-interacting protein 
      kinase 3 (RIPK3) in 51 patients with New York Heart Association (NYHA) class 
      III-IV heart failure, 53 patients with myocardial infarction with ST elevation 
      (STEMI), and 19 healthy subjects serving as a control group. An enzyme-linked 
      immunoadsorbent assay (ELISA) was used to measure the levels of RIPK3 expression 
      in serum. The area under the receiver operating characteristic curve (AUC) was 
      then used to evaluate the predictive performance of RIPK3 and troponin I in 
      patients with STEMI. In patients with normal levels of troponin I prior to 
      percutaneous coronary intervention (PCI), serum levels of RIPK3 and troponin I 
      after PCI were sufficient to differentiate patients with a preserved left 
      ventricular ejection fraction (LVEF) from those with impaired left ventricular 
      function after PCI (AUC = 0.780 (95% CI: 0.565-0.995, p = 0.043) with a 
      sensitivity of 76.9% and a specificity of 71.4% vs. AUC = 0.735 (95% CI: 
      0.530-0.941, p = 0.038) with a sensitivity of 88.2% and a specificity of 63.6% at 
      the optimal cutoff values, respectively). Moreover, elevated levels of troponin I 
      after PCI were associated with an increased risk of an LVEF < 50% prior to 
      discharge (odds ratio, 1.014; 95 % CI, 1.001 to 1.027; p = 0.03), while elevated 
      levels of RIPK3 were not associated with such a risk. The current findings 
      suggest that in patients with normal levels of troponin I prior to PCI, serum 
      levels of RIPK3 and troponin I can serve as a potential marker to identify 
      patients with a decreased LVEF, thus possibly allowing an early shift to more 
      intensive therapy.
FAU - Kashlov, Javor K
AU  - Kashlov JK
AD  - Department of Propedeutics of Internal Medicine, Medical University of Varna.
FAU - Donev, Ivan S
AU  - Donev IS
FAU - Doneva, Jordanka G
AU  - Doneva JG
FAU - Valkov, Veselin D
AU  - Valkov VD
FAU - Kirkorova, Arpine D
AU  - Kirkorova AD
FAU - Ghenev, Peter I
AU  - Ghenev PI
FAU - Conev, Nikolay V
AU  - Conev NV
FAU - Radeva, Temenuzhka R
AU  - Radeva TR
FAU - Ivanov, Borislav D
AU  - Ivanov BD
FAU - Georgieva, Zhaneta T
AU  - Georgieva ZT
LA  - eng
PT  - Journal Article
DEP - 20160718
PL  - Japan
TA  - Biosci Trends
JT  - Bioscience trends
JID - 101502754
RN  - 0 (Biomarkers)
RN  - 0 (Troponin I)
RN  - EC 2.7.11.1 (RIPK3 protein, human)
RN  - EC 2.7.11.1 (Receptor-Interacting Protein Serine-Threonine Kinases)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - ROC Curve
MH  - Receptor-Interacting Protein Serine-Threonine Kinases/*blood
MH  - ST Elevation Myocardial Infarction/diagnosis/*metabolism/physiopathology
MH  - Sensitivity and Specificity
MH  - Stroke Volume
MH  - Troponin I/*blood
MH  - *Ventricular Function, Left
EDAT- 2016/07/20 06:00
MHDA- 2017/02/07 06:00
CRDT- 2016/07/20 06:00
PHST- 2016/07/20 06:00 [entrez]
PHST- 2016/07/20 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
AID - 10.5582/bst.2016.01077 [doi]
PST - ppublish
SO  - Biosci Trends. 2016 Sep 5;10(4):294-9. doi: 10.5582/bst.2016.01077. Epub 2016 Jul 
      18.